PVR and neoplasm: In primary tumors, CD155 and CD112 have a potential role in tumor progression and migration [32] since interaction with TIGIT receptor expressed by lymphocytes and NK cells can inhibit the anti-tumor activity, including the maladaptation of granule releasing and IFN-γ production of these effector cells [33,34].